A Ropes & Gray team represented Sarepta Therapeutics in a global settlement and license agreements with BioMarin Pharmaceutical for the marketed Duchenne muscular dystrophy (DMD) therapy EXONDYS 51and all future exon-skipping drug treatments under a $35 million plus settlement of the companies’ patent dispute over the technology. The agreements were announced on July 18. Under terms of the agreement, Sarepta will pay BioMarin milestone and royalty payments with respect to drugs using the DMD technology.
The Ropes & Gray team was led by intellectual property transactions partner David McIntosh and included life sciences associate Rajarshi Banerjee (all of Boston).
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.